MedPath

Orphenadrine and Methocarbamol for LBP

Phase 4
Completed
Conditions
Low Back Pain
Interventions
Registration Number
NCT02665286
Lead Sponsor
Montefiore Medical Center
Brief Summary

Low back pain is a common cause of visit to emergency department. It is not clear if skeletal muscle relaxants are of benefit for patients with acute low back pain. This is a randomized study to determine if skeletal muscle relaxants, when combined with naproxen, improve outcomes more than naproxen alone

Detailed Description

Patients with acute, non-traumatic, non-radicular low back pain will be enrolled at the time of discharge from the emergency department. Participants will be followed by telephone one week and 3 months after the ED visit

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
240
Inclusion Criteria
  • LBP duration <= 2 weeks
  • No trauma to low back within previous month
  • No radicular symptoms
  • No history of low back pain or history of only infrequent episodes
Exclusion Criteria
  • Medication allergies or contra-indications
  • Not available for follow-up
  • Chronic pain syndrome

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboNaproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
PlaceboNaproxenNaproxen 500mg tablets taken twice per day + placebo. Placebo dose will be either 1 capsule orally twice per day or 1 or 2 capsules orally, thrice per day Naproxen 500mg po BID x 10 days #20 + Placebo
OrphenadrineOrphenadrineNaproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
OrphenadrineNaproxenNaproxen 500mg, orally twice per day + orphenadrine 100mg, orally twice per day for 10 days Naproxen 500mg po BID x 10 days #20 + Orphenadrine
MethocarbamolNaproxenNaproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
MethocarbamolMethocarbamolNaproxen 500mg tablets, orally twice per day + methocarbamol 750mg, orally as 1 or 2 tabs, thrice per day Naproxen 500mg po BID x 10 days #20 + Methocarbamol
Primary Outcome Measures
NameTimeMethod
Functional Impairment as Measured on the Roland Morris Disability Questionnaire1 week

Change in Roland Morris Disability Questionnaire between baseline and 1 week.

The low back pain functional disability scale is the RMDQ. The RMDQ is a 24-item low back pain functional scale recommended for use in low back pain research.Higher scores signify greater low back-related functional impairment.0= no functional impairment, 24= severe functional impairment.

Secondary Outcome Measures
NameTimeMethod
Cases of Moderate or Severe LBP1 week

Participants with moderate to severe low back pain after treatment as report on the following ordinal scale: severe, moderate, mild, or none

Medications--Patient Self Report of Medication Use1 week

Participants still using medication such as analgesics for LBP after treatment

Patient Satisfaction With Treatment1 week

The number of participants with affirmative response to the following question: Do you want the same medication combination during a subsequent episode of LBP. This is a patient-centered outcome that allows each individual to determine the desirability of the intervention.

Trial Locations

Locations (1)

Montefiore Medical Center

🇺🇸

Bronx, New York, United States

© Copyright 2025. All Rights Reserved by MedPath